Earnings summaries and quarterly performance for Kymera Therapeutics.
Executive leadership at Kymera Therapeutics.
Nello Mainolfi
Detailed
President and Chief Executive Officer
CEO
BA
Brian Adams
Detailed
Chief Legal Officer and Corporate Secretary
BJ
Bruce Jacobs
Detailed
Chief Financial Officer
JG
Jared Gollob
Detailed
Chief Medical Officer
JC
Jeremy Chadwick
Detailed
Chief Operating Officer
NG
Noah Goodman
Detailed
Chief Business Officer
Board of directors at Kymera Therapeutics.
Research analysts who have asked questions during Kymera Therapeutics earnings calls.
Andy Chen
Wolfe Research, LLC
4 questions for KYMR
Also covers: ARGX, CRNX, IMVT +7 more
Faisal Khurshid
Leerink Partners
4 questions for KYMR
Also covers: ABCL, ANIP, GERN +4 more
JM
Jeet Mukherjee
Leerink Partners
3 questions for KYMR
Also covers: ARVN, BCAB, KURA +4 more
Jeff Jones
Oppenheimer & Co. Inc.
3 questions for KYMR
Also covers: ABEO, CLRB, CMMB +8 more
MF
Marc Frahm
TD Cowen
3 questions for KYMR
Also covers: ADAP, AGIO, BPMC +7 more
BC
Bradley Canino
Stifel
2 questions for KYMR
Also covers: ARVN, CELC, KURA +2 more
EM
Eliana Merle
UBS
2 questions for KYMR
Also covers: ALNY, APLS, ARVN +17 more
Eric Joseph
JPMorgan Chase & Co.
2 questions for KYMR
Also covers: BEAM, BLUE, ENTA +9 more
KP
Kalpit Patel
B. Riley Securities
2 questions for KYMR
Also covers: DERM, FBRX, GERN +4 more
Kelly Shi
Jefferies
2 questions for KYMR
Also covers: ADCT, AGEN, ALDX +17 more
Michael Schmidt
Guggenheim Securities
2 questions for KYMR
Also covers: ADAP, ADCT, ARVN +19 more
Paul Jeng
Guggenheim Partners
2 questions for KYMR
Also covers: ADAP, BPMC, IMCR +2 more
SL
Sudan Loganathan
Stephens Inc.
2 questions for KYMR
Also covers: ADCT, ARVN, BPMC +6 more
AS
Alexei Siniakov
Truist Securities
1 question for KYMR
Alex Thompson
Stifel Financial Corp.
1 question for KYMR
Also covers: ARGX, ASND, CRNX +1 more
AN
Andrea Newkirk
Goldman Sachs
1 question for KYMR
Also covers: ABCL, ALKS, ARWR +9 more
Derek Archila
Wells Fargo
1 question for KYMR
Also covers: APLS, ARGX, ARVN +9 more
DS
Dingding Shi
Jefferies
1 question for KYMR
Also covers: ADCT, ASND, AUTL +6 more
EM
Ellie Merle
UBS Group AG
1 question for KYMR
Also covers: ALNY, ALT, ARVN +12 more
EW
Eric Wong
The Goldman Sachs Group, Inc.
1 question for KYMR
Eva Fortea-Verdejo
Wells Fargo Securities
1 question for KYMR
Also covers: EXEL, KNSA, RCUS
GE
Gospel Enyindah-Asonye
Morgan Stanley
1 question for KYMR
Also covers: RGNX, VTYX
Judah Frommer
Morgan Stanley
1 question for KYMR
Also covers: APLS, ARQT, ATAI +4 more
KD
Kripa Devarakonda
Truist Securities
1 question for KYMR
Also covers: ABCL, ARVN, BMY +5 more
Mayank Mamtani
B. Riley Securities
1 question for KYMR
Also covers: AGEN, ALT, ARWR +18 more
Parth Patel
Morgan Stanley
1 question for KYMR
Also covers: AXSM
RF
Ron Feiner
Leerink Partners
1 question for KYMR
Also covers: WVE
Sam Slutsky
LifeSci Capital, LLC
1 question for KYMR
Also covers: ALXO, PVLA, RAIN +1 more
SD
Srikripa Devarakonda
Truist Financial Corporation
1 question for KYMR
Also covers: ABCL, ABSI, AFMD +12 more
TA
Tazeen Ahmad
Bank of America
1 question for KYMR
Also covers: ACAD, ALNY, APLS +20 more
VP
Vikram Purohit
Morgan Stanley
1 question for KYMR
Also covers: ABSI, ARGX, ARQT +11 more
Recent press releases and 8-K filings for KYMR.
Kymera Therapeutics Closes Upsized Public Offering
KYMR
New Projects/Investments
- Kymera Therapeutics closed its upsized underwritten public offering of $602.0 million of common stock.
- The offering included the full exercise by the underwriters of their option to purchase additional shares.
- A total of 8,050,000 shares of common stock were sold at a public offering price of $86.00 per share.
- The gross proceeds to Kymera from the offering were approximately $692.3 million before deducting underwriting discounts and estimated offering expenses.
Dec 11, 2025, 9:01 PM
Kymera Therapeutics Receives FDA Fast Track Designation for KT-621
KYMR
Product Launch
New Projects/Investments
- Kymera Therapeutics announced that the U.S. FDA has granted Fast Track designation to KT-621, its first-in-class, oral STAT6 degrader, for the treatment of moderate to severe atopic dermatitis (AD).
- This designation is supported by positive results from the KT-621 BroADen Phase 1b AD patient trial.
- The BROADEN2 Phase 2b AD trial is ongoing, with data expected by mid-2027, and the BREADTH Phase 2b trial in asthma is planned to initiate in Q1 2026.
- The Fast Track designation is intended to accelerate the development and review of therapies for serious conditions with unmet medical needs, potentially leading to faster market access.
Dec 11, 2025, 12:00 PM
Kymera Therapeutics Announces Pricing of Upsized Public Offering and Full Option Exercise
KYMR
- Kymera Therapeutics announced the pricing of its underwritten public offering, selling 7,000,000 shares of common stock at a public offering price of $86.00 per share.
- The underwriters exercised their option in full on December 10, 2025, to purchase an additional 1,050,000 shares of common stock.
- The company expects to receive estimated net proceeds of approximately $656.1 million from the offering.
- The offering is expected to close on December 11, 2025.
- Net proceeds will be used to advance its pipeline of preclinical and clinical degrader programs, and for working capital and other general corporate purposes.
Dec 10, 2025, 10:17 PM
Kymera Therapeutics Prices $602 Million Public Offering
KYMR
New Projects/Investments
- Kymera Therapeutics announced the pricing of an underwritten public offering of $602.0 million of its common stock.
- The company is selling 7,000,000 shares at a public offering price of $86.00 per share.
- Underwriters have a 30-day option to purchase up to an additional 1,050,000 shares.
- The offering is expected to close on December 11, 2025.
- Kymera intends to use the net proceeds to advance its pipeline of preclinical and clinical degrader programs, and for working capital and other general corporate purposes.
Dec 10, 2025, 4:30 AM
Kymera Therapeutics Announces Proposed Public Offering
KYMR
New Projects/Investments
- Kymera Therapeutics has commenced an underwritten public offering of $500.0 million of its common stock.
- The company intends to grant the underwriters a 30-day option to purchase up to an additional $75.0 million of shares.
- Net proceeds from the offering will be used to advance its pipeline of preclinical and clinical degrader programs, and for working capital and other general corporate purposes.
- The offering is being managed by Morgan Stanley, J.P. Morgan, Jefferies, Stifel, Guggenheim Securities, and Wells Fargo Securities as joint book-running managers.
Dec 8, 2025, 9:01 PM
Kymera Therapeutics Announces Positive Phase 1b Results for Oral STAT6 Degrader KT-621
KYMR
Product Launch
New Projects/Investments
- Kymera Therapeutics, Inc. (KYMR) announced positive Phase 1b results for its oral STAT6 degrader, KT-621, in moderate to severe atopic dermatitis (AD) patients on December 8, 2025.
- The BroADen study demonstrated deep STAT6 degradation (98% in blood and 94% in skin) and robust reductions in Type 2 biomarkers, along with meaningful improvements in clinical endpoints such as EASI, SCORAD, and itch.
- KT-621 exhibited a favorable safety profile and its efficacy results were in line with or numerically exceeded published data for Dupilumab at Week 4.
- These results support the continued development of KT-621, with the BROADEN2 Phase 2b study in AD ongoing and the BREADTH Phase 2b study in asthma anticipated to start in Q1 2026.
Dec 8, 2025, 1:45 PM
Kymera Therapeutics Reports Positive Phase I-B Clinical Data for Oral STAT6 Degrader KT-621
KYMR
Product Launch
New Projects/Investments
- Kymera Therapeutics announced positive results from its BroADen phase I-B trial for KT-621, an oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD).
- KT-621 demonstrated robust clinical activity, achieving 62% and 63% mean reductions in EASI by day 29 in the 100 mg and 200 mg dose groups, respectively, and an overall 76% EASI-50 responder rate.
- The drug showed significant reductions in Type 2 biomarkers in blood, skin, and lungs, with effects comparable to or numerically exceeding published dupilumab data at week four.
- KT-621 was well-tolerated with a favorable safety profile, reporting no serious adverse events (SAEs), severe adverse events (AEs), or dose-dependent treatment-emergent adverse events (TEAEs).
- Early evidence of activity was also observed in patients with comorbid asthma and allergic rhinitis, supporting advancement into phase II-B trials for AD and asthma.
Dec 8, 2025, 1:00 PM
Kymera Reports Positive Phase 1b Results for Oral STAT6 Degrader KT-621 in Atopic Dermatitis
KYMR
New Projects/Investments
- Kymera's oral STAT6 degrader, KT-621, demonstrated deep degradation in blood and skin, and a profound effect on type 2 inflammation biomarkers in patients with moderate to severe atopic dermatitis.
- The Phase 1b trial showed robust clinical activity in AD, achieving Dupilumab-like effects on key endpoints such as EASI and pruritus NRS, and in some cases numerically exceeding Dupilumab results at week four.
- KT-621 was well tolerated with a favorable safety profile, similar to healthy volunteer data, and notably, no instances of conjunctivitis were observed.
- Following these results, Kymera has initiated a Phase 2B trial for moderate to severe AD and plans to start a Phase 2B asthma study next quarter, aiming to address a significant unmet need in type 2 inflammatory diseases.
Dec 8, 2025, 1:00 PM
Kymera Therapeutics Announces Positive KT-621 Phase 1b BroADen Study Results
KYMR
Product Launch
New Projects/Investments
- Kymera Therapeutics announced positive Phase 1b results for KT-621, an oral STAT6 degrader for Type 2 allergic and atopic diseases, from the BroADen study on 2025-12-08.
- The study demonstrated deep STAT6 degradation in both blood (98%) and skin (94%) after 4 weeks of treatment in Atopic Dermatitis (AD) patients.
- KT-621 showed robust reductions in Type 2 biomarkers and meaningful improvements in clinical endpoints for AD, including EASI, SCORAD, and patient-reported outcomes.
- The drug was well-tolerated with a favorable safety profile, reporting no serious adverse events or dose-dependent patterns in treatment-emergent adverse events.
- These results suggest KT-621 has the potential for a dupilumab-like profile as a once-daily, oral treatment for Type 2 diseases.
Dec 8, 2025, 1:00 PM
Kymera Therapeutics Reports Positive Phase 1b KT621 Results for Atopic Dermatitis
KYMR
Product Launch
New Projects/Investments
- Kymera Therapeutics announced positive Phase 1b clinical trial results for KT621, an oral STAT6 degrader, in patients with moderate to severe atopic dermatitis (AD).
- The trial demonstrated deep STAT6 degradation in blood and skin, achieving 98% degradation in blood by day eight and 94% in skin after four weeks of treatment.
- KT621 showed robust clinical activity in AD patients, including a 63% mean reduction in EASI and a 76% overall EASI50 responder rate by day 29, with results comparable to or numerically exceeding published Dupilumab data at week four.
- The drug was well-tolerated with a favorable safety profile, and also demonstrated early evidence of activity in comorbid asthma and allergic rhinitis.
- Kymera plans to advance KT621 into Phase 2B trials for AD and asthma.
Dec 8, 2025, 1:00 PM
Quarterly earnings call transcripts for Kymera Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more